Clinical and morphologic data of the 45 patients with T-MF and statistical survival analysis
| Grouping . | No. of Patients . | No. of Death . | Median Survival (mo) . | % Patients Alive at 2 Yr (95% CI) . | % Patients Alive at 5 Yr (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Men | 26 | 16 | 30 | 52.5 | 18.9 | .09 |
| Women | 19 | 10 | 48 | 72.2 | 27.1 | |
| Age | ||||||
| Younger than 60 y | 14 | 6 | 36 | 69.8 | 46.6 | .09 |
| At least 60 y | 31 | 20 | 30 | 56.5 | 6.8 | |
| Interval from MF diagnosis to transformation | ||||||
| Less than 2 y | 10 | 6 | 30 | 51.4 | — | .31 |
| At least 2 y | 35 | 20 | 38 | 62.9 | 23.9 | |
| Stage at transformation | ||||||
| I-IIA | 2 | 0 | — | — | — | * |
| IIB | 24 | 13 | 48 | 69.3 | 26.9 | |
| III | 1 | 1 | — | — | — | |
| IV | 18 | 12 | 30 | 52.5 | 10.6 | |
| Transformation staging | ||||||
| T2 | 5 | 3 | 7 | — | — | .24 |
| T3 | 40 | 23 | 36 | 62.3 | 22.5 | |
| Extracutaneous spreading | ||||||
| No | 24 | 11 | 48 | 74.1 | 32.0 | .02 |
| Yes | 20 | 15 | 22 | 45.7 | 7.8 | |
| Percentage large T-cells | ||||||
| 25%-49% | 7 | 3 | 15 | 44.4 | — | .47 |
| 50%-79% | 19 | 12 | 38 | 66.3 | 10.1 | |
| 80%-100% | 19 | 11 | 33 | 61.8 | 32.1 | |
| CD30 staining | ||||||
| None | 31 | 20 | 30 | 54.3 | 14.1 | .14 |
| Positivity at fewer than 75% | 7 | 3 | 60 | 85.7 | 28.6 | |
| Positivity at 75% or more | 7 | 3 | 38 | 66.6 | 44.4 | |
| CD20 staining† | ||||||
| Negative | 22 | 16 | 30 | 47.4 | 13.9 | .27 |
| Positive | 18 | 8 | 38 | 75.3 | 27.8 |
| Grouping . | No. of Patients . | No. of Death . | Median Survival (mo) . | % Patients Alive at 2 Yr (95% CI) . | % Patients Alive at 5 Yr (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Men | 26 | 16 | 30 | 52.5 | 18.9 | .09 |
| Women | 19 | 10 | 48 | 72.2 | 27.1 | |
| Age | ||||||
| Younger than 60 y | 14 | 6 | 36 | 69.8 | 46.6 | .09 |
| At least 60 y | 31 | 20 | 30 | 56.5 | 6.8 | |
| Interval from MF diagnosis to transformation | ||||||
| Less than 2 y | 10 | 6 | 30 | 51.4 | — | .31 |
| At least 2 y | 35 | 20 | 38 | 62.9 | 23.9 | |
| Stage at transformation | ||||||
| I-IIA | 2 | 0 | — | — | — | * |
| IIB | 24 | 13 | 48 | 69.3 | 26.9 | |
| III | 1 | 1 | — | — | — | |
| IV | 18 | 12 | 30 | 52.5 | 10.6 | |
| Transformation staging | ||||||
| T2 | 5 | 3 | 7 | — | — | .24 |
| T3 | 40 | 23 | 36 | 62.3 | 22.5 | |
| Extracutaneous spreading | ||||||
| No | 24 | 11 | 48 | 74.1 | 32.0 | .02 |
| Yes | 20 | 15 | 22 | 45.7 | 7.8 | |
| Percentage large T-cells | ||||||
| 25%-49% | 7 | 3 | 15 | 44.4 | — | .47 |
| 50%-79% | 19 | 12 | 38 | 66.3 | 10.1 | |
| 80%-100% | 19 | 11 | 33 | 61.8 | 32.1 | |
| CD30 staining | ||||||
| None | 31 | 20 | 30 | 54.3 | 14.1 | .14 |
| Positivity at fewer than 75% | 7 | 3 | 60 | 85.7 | 28.6 | |
| Positivity at 75% or more | 7 | 3 | 38 | 66.6 | 44.4 | |
| CD20 staining† | ||||||
| Negative | 22 | 16 | 30 | 47.4 | 13.9 | .27 |
| Positive | 18 | 8 | 38 | 75.3 | 27.8 |